EagleClaw Capital Management’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$2.13M Sell
1,772
-25
-1% -$25.5K 0.29% 70
2026
Q1
$1.65M Buy
1,797
+27
+2% +$27.4K 0.23% 79
2025
Q4
$1.9M Sell
1,770
-50
-3% -$47.8K 0.28% 79
2025
Q3
$1.39M Buy
1,820
+105
+6% +$78.1K 0.19% 86
2025
Q2
$1.34M Buy
1,715
+7
+0.4% +$5.44K 0.2% 86
2025
Q1
$1.41M Sell
1,708
-10
-0.6% -$8.32K 0.22% 83
2024
Q4
$1.33M Hold
1,718
0.21% 83
2024
Q3
$1.52M Sell
1,718
-7
-0.4% -$6.29K 0.25% 79
2024
Q2
$1.56M Hold
1,725
0.28% 80
2024
Q1
$1.34M Sell
1,725
-60
-3% -$42.7K 0.24% 82
2023
Q4
$1.04M Hold
1,785
0.22% 83
2023
Q3
$959K Hold
1,785
0.22% 81
2023
Q2
$837K Sell
1,785
-25
-1% -$10.5K 0.19% 88
2023
Q1
$622K Buy
1,810
+185
+11% +$62.4K 0.15% 94
2022
Q4
$594K Buy
1,625
+975
+150% +$346K 0.14% 93
2022
Q3
$210K Hold
650
0.06% 123
2022
Q2
$211K Sell
650
-50
-7% -$15K 0.06% 123
2022
Q1
$200K Sell
700
-50
-7% -$12.9K 0.05% 134
2021
Q4
$207K Buy
+750
New +$190K 0.05% 138

Other funds holding LLY

EagleClaw Capital Management's LLY Position: Q2 2026 in Review

EagleClaw Capital Management reduced its Eli Lilly (LLY) stake by 1.4% in Q2 2026, selling an estimated $25.5K and leaving 1,772 shares worth $2.13M. The position accounts for 0.29% of the portfolio, ranked #70.

EagleClaw Capital Management first reported a position in LLY in Q4 2021 and has held it in 19 quarters since. 4,633 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • EagleClaw Capital Management held 1,772 shares of Eli Lilly worth $2.13M as of Q2 2026.
  • EagleClaw Capital Management sold 25 Eli Lilly shares in Q2 2026, an estimated $25.5K.
  • Eli Lilly made up 0.29% of EagleClaw Capital Management's portfolio in Q2 2026, its #70 holding.
  • EagleClaw Capital Management first reported a position in Eli Lilly in Q4 2021 and has held it in 19 quarters since.
  • 4,633 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on EagleClaw Capital Management's 13F filing for Q2 2026, filed 10 Aug 2026.